% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Wenger:305684,
      author       = {V. Wenger and G. Garcia-Manero and R. Zeiser$^*$ and M.
                      Lübbert$^*$},
      title        = {{DNA} methyltransferase inhibitors in hematological
                      malignancies and solid tumors.},
      journal      = {International journal of cancer},
      volume       = {158},
      number       = {2},
      issn         = {0020-7136},
      address      = {Bognor Regis},
      publisher    = {Wiley-Liss},
      reportid     = {DKFZ-2025-02307},
      pages        = {433-461},
      year         = {2026},
      note         = {Volume158, Issue2, Special issue: Principles of Chromatin
                      Remodeling in Cancer and Translational Perspectives, 15
                      January 2026, Pages 433-461 / invited review},
      abstract     = {Epigenetic modifications such as DNA methylation play a
                      fundamental role in oncogenesis and the progression of
                      neoplasms neoplasias. DNA methyltransferase inhibitors
                      (DNMTi) constitute a family of therapeutic agents that
                      impede the methylation at the 5-position on cytosine
                      nucleotides, thereby modulating the epigenetic regulation of
                      tumor suppressor genes, oncogenes, and other key regulatory
                      genes. The first-generation DNMTi azacitidine and decitabine
                      have demonstrated substantial efficacy in the treatment of
                      medically non-fit, older patients with acute myeloid
                      leukemia (AML) or myelodysplastic syndrome (MDS) ineligible
                      for intensive chemotherapy (IC), by virtue of their
                      favorable safety profile. Despite these clinical
                      achievements, however, single-agent DNMTi treatment has
                      faced challenges such as limited, non-durable response rates
                      and remissions as well as the emergence of secondary
                      resistance. These limitations have driven broad efforts to
                      identify more effective, dual treatment combinations, such
                      as now attained with the DNMTi-BCL-2 (B-cell lymphoma 2)
                      inhibitor combination. This review aims to provide a
                      comprehensive overview and analysis of the pivotal role of
                      DNMTi in both mono- and combination therapies for myeloid
                      malignancies over the last 40 years, while also exploring
                      their potential applicability in lymphoid malignancies.
                      Additionally, this review assesses the therapeutic potential
                      of DNMTi in the management of solid tumors. Through these
                      discussions, we intend to enhance the understanding of the
                      mechanistic and therapeutic implications of DNMTi across a
                      diverse array of malignancies.},
      subtyp        = {Review Article},
      keywords     = {differentiation (Other) / epigenetic therapy (Other) /
                      hypomethylating agents (Other) / retinoic acid (Other) /
                      venetoclax (Other)},
      cin          = {FR01},
      ddc          = {610},
      cid          = {I:(DE-He78)FR01-20160331},
      pnm          = {899 - ohne Topic (POF4-899)},
      pid          = {G:(DE-HGF)POF4-899},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:41204420},
      doi          = {10.1002/ijc.70197},
      url          = {https://inrepo02.dkfz.de/record/305684},
}